AL101 is an investigational human Announced new non-exclusive data license with GSK, introduced 23andMe Total Health™, and received FDA clearance for IND on novel, dual-mechanism immuno-oncology asset ...

URAC, the nation's largest and most comprehensive independent health care accreditation organization, today announced the launch of its updated Telehealth Accreditation program. The revised ...

Shields has been vocal about women's wellness and now backs an initiative for women to be aware of an infection that's ...

If automation is to become a key partner in experiment design and a core component of modern lab infrastructure, it is ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

The Jersey City, New Jersey-based company said it had a loss ... milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the ...

Sales of Tezspire reached $653 million last year, fuelled by the launch of a new self-injector version. Other potential ...

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK's specialty medicines segment showed strong performance, growing over 20% due to successful new launches. Additionally, GSK is currently undervalued, trading at £16.1, significantly below the ...

GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...